Leiden University Medical Center, Leiden, The Netherlands

Endocrinology Research Laboratory and Department of Endocrinology

[Group description | Scientific staff | Publications within DiMI]

References

  1. Deckers M, van Dinther M, Buijs J, Que I, Lowik C, van der Pluijm G, ten Dijke P. The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. Cancer Res. 2006 66(4):2202-9
  2. van Bezooijen RL, Papapoulos SE, Lowik CW. Bone morphogenetic proteins and their antagonists: the sclerostin paradigm. J Endocrinol Invest. 2005;28(8 Suppl):15-7.
  3. van der Horst G, Farih-Sips H, Lowik CW, Karperien M. Multiple mechanisms are involved in inhibition of osteoblast differentiation by PTHrP and PTH in KS483 Cells. J Bone Miner Res. 2005 Dec;20(12):2233-44
  4. de Boer J, van Blitterswijk C, Lowik C. Bioluminescent imaging: emerging technology for non-invasive imaging of bone tissue engineering. Biomaterials. 2006 Mar;27(9):1851-8.
  5. van der Pluijm G, Que I, Sijmons B, Buijs JT, Lowik CW, Wetterwald A, Thalmann GN, Papapoulos SE, Cecchini MG. Interference with the microenvironmental support impairs the de novo formation of bone metastases in vivo. Cancer Res. 2005 Sep 1;65(17):7682-90.
  6. Franke-Fayard B, Janse CJ, Cunha-Rodrigues M, Ramesar J, Buscher P, Que I, Lowik et al. Murine malaria parasite sequestration: CD36 is the major receptor, but cerebral pathology is unlinked to sequestration.Proc Natl Acad Sci U S A. 2005; 102(32):11468-73.
  7. van Bezooijen RL, ten Dijke P, Papapoulos SE, Lowik CW. SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev. 2005 Jun;16(3):319-27.
  8. Lowik CW, Cecchini MG, Maggi A, van der Pluijm G. Noninvasive real-time in vivo bioluminescent imaging of gene expression and of tumor progression and metastasis. Ernst Schering Res Found Workshop. 2005;(49):193-227.
  9. van Bezooijen RL, Roelen BA, Visser A, van der Wee-Pals L, de Wilt E, Karperien M, Hamersma H, Papapoulos SE, ten Dijke P, Lowik CW. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med. 2004 Mar 15;199(6):805-14.
  10. van der Pluijm G, Deckers M, Sijmons B, de Groot H, Bird J, Wills R, Papapoulos S, Baxter A, Lowik C. In vitro and in vivo endochondral bone formation models allow identification of anti-angiogenic compounds. Am J Pathol. 2003 Jul;163(1):157-63.
  11. Ciana P, Raviscioni M, Mussi P, Vegeto E, Que I, Parker MG, Lowik C, Maggi, In vivo imaging of transcriptionally active estrogen receptors.Nature Medicine. 2003; 9:82-6.
  12. Wetterwald A, van der Pluijm G, Que I, Sijmons B, Buijs J, Karperien M, Lowik CW, Gautschi E, Thalmann GN, Cecchini MG. Optical imaging of cancer metastasis to bone marrow: a mouse model of minimal residual disease. Am J Pathol. 2002; 160:1143-53.
  13. van der Pluijm G, Sijmons B, Vloedgraven H, van der Bent C, Drijfhout JW, Verheijen J, Quax P, Karperien M, Papapoulos S, Lowik C. Urokinase-receptor/integrin complexes are functionally involved in adhesion and progression of human breast cancer in vivo. Am J Pathol 2001;159:971-82
  14. van der Pluijm G, Sijmons B, Vloedgraven H, Deckers M, Papapoulos S, Lowik C. Monitoring metastatic behavior of human tumour cells in mice with species-specific polymerase chain reaction: elevated expression of angiogenesis and bone resorption stimulators by breast cancer in bone metastases. J Bone Miner Res. 2001;16: 1077-91.
  15. Yamaguchi N, Anand-Apte B, Lee M, Sasaki T, Fukai N, Shapiro R, Que I, Lowik C, Timpl R, Olsen BR. Endostatin inhibits VEGF-induced endothelial cell migration and tumour growth independently of zinc binding. EMBO J. 1999; 18:4414-23.